To help accelerate the lymphocyte recovery, tapering the immunosuppressant therapy should be attempted. 8 However, this is not possible in most cases because of the development of acute GVHD, or even when it is possible, lymphocyte recovery does not always occur. We herein reported a case that developed disseminated-AdV disease after allo-SCT and was successfully treated by plasma exchange (PE) even under lymphopenic conditions.
A 2-year-old boy with ALL in relapse underwent allogeneic BMT from an human leukocyte Ag-matched unrelated donor. The conditioning regimen consisted of fractionated TBI (2 Gy Â 6), etoposide (60 mg/kg) Â 1 day and CY (60 mg/kg) Â 2 days. Tacrolimus and short-term MTX were administered for the prophylaxis of acute GVHD. On day 19 after SCT, myeloid engraftment (ANC 4500 cells/mL) was achieved. However, the patient developed grade-III (skin 3, gut 2, liver 0) acute GVHD on day 9, which was barely resolved with 2 mg/kg/day prednisolone and additional administration of MTX (10 mg/m 2 , on day 28, 31, 35, 42, 51). On day 19, the patient suddenly developed painful, gross hematuria with persistent fever despite broad-spectrum antibiotic therapy. Abdominal ultrasonography and computed tomographic scans showed the development of bilateral hydronephrosis. As adenovirus 11 was isolated from his urine, which was confirmed by PCR, treatment with cidofovir (i.v. at 1 mg/kg 3 times a week) in combination with probenecid was initiated on day 29. From day 31, the patient's total lymphocyte count was decreased to less than 3 Â 10 2 cells/mL. Although the administration of cidofovir was continued, his hematuria persisted, and his renal function deteriorated. Detection of AdV by RQ-PCR was positive in the plasma (1.5 Â 10 4 copies/mL) on day 35. No other viruses (CMV, EBV and HSV) were detected. Prednisolone was tapered to a final dose of 0.8 mg/kg/day in an attempt to alleviate the immunosuppressive state, but the lymphocyte count did not increase.
On day 63, he developed impairment of consciousness, incoherent speech and motor weakness. A magnetic resonance imaging of the brain showed multiple micro-hemorrhages and cytotoxic edema detected in the brain stem, thalamus and posterior limb of the internal capsule. A cerebrospinal fluid analysis revealed elevated levels of protein (215 mg/dL) and myelin basic protein (305 pg/mL), but the cell count (2 cells/mL) was not elevated. The cerebrospinal fluid was positive for AdV as determined by RQ-PCR (1.3 Â 10 3 copies/mL). The patient's plasma AdV load was increased further (5.9 Â 10 5 copies/mL) despite continuation of cidofovir. Accordingly, we diagnosed him to have acute encephalitis associated with AdV infection.
The laboratory data showed that his blood urea nitrogen level was 126.5 mg/dL and his serum creatinine level was 2.6 mg/dL and, as a result, continuous hemodiafiltration was started on day 63. PE was started to remove the overproduced inflammatory cytokines and AdV on day 65. Prompt clinical improvement was observed following the first session of PE, with resolution of the fever, recovery of lymphocytopenia and a temporal improvement in renal failure. The total lymphocyte count increased rapidly up to 1061 cells/mL on day 68. The plasma AdV load, as assessed by RQ-PCR, decreased to 3.1 Â 10 3 copies/mL 1 week after a single session of PE, and was undetectable (o100 copies/mL) 1 month later. The liquor AdV load was also undetectable (o100 copies/ mL) 1 month later (Figure 1 ). Although the patient suffered severe neurological damage and had to be maintained on hemodialysis due to persistent renal failure, he is still alive and in continuous hematological remission.
The reason that the very high plasma viral load persisted despite a continuation of cidofovir might be that the patient had become profoundly lymphopenic (Figure 1) . One possible explanation for his severe lymphocytopenia could be due to the fact that prednisolone and MTX successfully suppressed the acute GVHD, but these treatments also resulted in profound immunosuppression. Another reason was considered to be that AdV itself could induce lymphocytopenia. A delayed lymphocyte recovery, especially, a lymphocyte count less than 300 cells/mL, has been identified as a risk factor for disseminated AdV disease. 6, 7 We speculate that PE therapy might remove the AdV directly, and significantly reduce the humoral mediators which suppressed the lymphocytes. Although the effect is temporary, PE therapy dramatically decreases the virus load in a very short time. 9, 10 In our case, as the lymphocyte count recovered immediately after PE therapy, the AdV was therefore considered to have been eradicated. The role of cidofovir therapy in this patient was difficult to elucidate as the patient's condition continued to deteriorate despite receiving treatment until PE therapy was performed.
To the best of our knowledge, this is the first report to describe the effect of PE therapy on cases presenting with disseminatedAdV disease. Our experience suggests that PE might be a therapeutic tool for treating disseminated AdV refractory to cidofovir therapy.
